An experimental form of immunotherapy could identify and eliminate cancer-driving blood cells harboring a specific mutation while sparing most healthy cells, making it a promising therapeutic strategy for myelofibrosis and related cancers, a study found. The study, led by researchers at University College London (UCL) and the University…
News
Eli Lilly’s AJ1-11095, an experimental JAK2 inhibitor recently licensed from Ajax Therapeutics, may be safe and effective at easing symptoms of myelofibrosis in patients whose disease has stopped responding to first-generation JAK2 inhibitors. That’s according to initial results from AJX-101 (NCT06343805), an open-label Phase 1 clinical…
Treatment with Disc Medicine’s investigational therapy DISC-0974 was tied to easing of fatigue, as well as a drop in overall symptoms, among certain myelofibrosis patients with cancer-associated anemia in a clinical trial called RALLY-MF. Updated results from the trial’s Phase 2 portion show that half of the major responders…
Adding the investigational therapy selinexor to an approved regimen of Jakafi (ruxolitinib) in the Phase 3 SENTRY trial led to a greater reduction in spleen size and may have improved survival for participants with myelofibrosis, according to selinexor’s developer, Menarini Group. “The strength of the spleen…
An elderly woman with primary myelofibrosis experienced disease worsening despite being on treatment with hydroxyurea and was later found to have a rare mutation in the CALR gene that had been missed by routine genetic testing. According to clinicians, the woman’s “clinical progression prompted repeat [blood] and molecular evaluation,” with…
Circulating myeloblasts (CMB), a type of immature white blood cell commonly found in the bloodstream of people with myelofibrosis, may serve as a marker of disease severity and outcomes, according to a pilot study. Blood levels of myeloblasts, measured by a sensitive technique called flow cytometry, correlated with established…
Treatment with DISC-0974, Disc Medicine’s experimental antibody therapy for myelofibrosis-associated anemia, led to durable anemia responses across patient subgroups and clinically significant fatigue improvements in certain groups of people with myelofibrosis, according to updated Phase 2 trial data. The Phase 1b/2 clinical trial, called RALLY-MF (NCT05320198), is…
Cero Therapeutics is expanding enrollment in an early clinical trial that’s testing its T-cell-based therapy candidate CER-1236, to now include people with hard-to-treat myelofibrosis. The Phase 1/1b CERTAIN-T study (NCT06834282) is a first-in-human, open-label trial — meaning both participants and investigators know the treatment being given to…
Treatment with Vonjo (pacritinib) before a stem cell transplant safely eased symptoms and spleen enlargement in people with myelofibrosis, while also allowing most patients to undergo their planned procedure, according to final findings from a Phase 2 trial. The findings support Vonjo as a “feasible and effective symptomatic treatment” for…
Eli Lilly is acquiring Ajax Therapeutics to advance AJ1-11095, an experimental next-generation JAK2 inhibitor designed to deliver deeper, longer-lasting benefits for patients with myelofibrosis and other blood cancers that do not respond well to existing treatments. “Lilly has long believed in the approach and is excited…
Recent Posts
- Targeted immunotherapy hits cancer-driving cells, spares others
- Experimental drug safely eases resistant myelofibrosis symptoms
- A weeklong trek abroad exemplifies how I’m living my best life
- Injection therapy eases fatigue for those with cancer-related anemia
- How to manage expectations about advances in myelofibrosis treatment